China Biologic Products Inc. (NASDAQ:CBPO) shares saw strong trading volume on Monday . 238,578 shares changed hands during trading, a decline of 3% from the previous session’s volume of 244,846 shares.The stock last traded at $115.44 and had previously closed at $115.98.

A number of equities research analysts have recently weighed in on the stock. Jefferies Group restated a “buy” rating on shares of China Biologic Products in a research note on Saturday, June 4th. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Wednesday, June 1st. Finally, Credit Suisse Group AG upgraded shares of China Biologic Products from a “neutral” rating to an “outperform” rating in a research note on Tuesday, July 5th.

The stock’s 50-day moving average price is $117.95 and its 200 day moving average price is $115.31. The firm has a market capitalization of $3.09 billion and a price-to-earnings ratio of 33.11.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.10. During the same quarter in the prior year, the firm posted $1.06 earnings per share. The firm earned $91.40 million during the quarter, compared to the consensus estimate of $87.60 million. The company’s revenue was up 15.6% on a year-over-year basis. Equities research analysts expect that China Biologic Products Inc. will post $4.20 earnings per share for the current year.

In related news, insider Zhijing Cbpo Liu sold 1,968 shares of the business’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $124.32, for a total value of $244,661.76. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Wenfang Liu sold 2,900 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $360,528.00. Following the completion of the sale, the director now owns 3,383 shares in the company, valued at $420,574.56. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in China Biologic Products stock. Employees Retirement System of Texas purchased a new stake in shares of China Biologic Products Inc. (NASDAQ:CBPO) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,846,000. Employees Retirement System of Texas owned about 0.08% of China Biologic Products at the end of the most recent quarter.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.